Search

Your search keyword '"Mues, Christoph"' showing total 9 results
Start Over Author "Mues, Christoph" Search Limiters Available in Library Collection
9 results on '"Mues, Christoph"'

1. Early Outcomes of 2 Mitral Valve Transcatheter Leaflet Approximation Devices: A Propensity Score–Matched Multicenter Comparison

Author

Mauri, Victor, Sugiura, Atsushi, Spieker, Max, Iliadis, Christos, Horn, Patrick, Öztürk, Can, Besler, Christian, Riebisch, Matthias, Al-Hammadi, Osamah, Ruf, Tobias, Gerçek, Muhammed, Grothusen, Christina, Mehr, Michael, Becher, Marc Ulrich, Mues, Christoph, Boeder, Niklas, Kreidel, Felix, Friedrichs, Kai, Westenfeld, Ralf, Braun, Daniel, Baldus, Stephan, Rassaf, Tienush, Thiele, Holger, Nickenig, Georg, Hausleiter, Jörg, Möllmann, Helge, Kelm, Malte, Rudolph, Volker, von Bardeleben, Ralph Stephan, Nef, Holger M., Luedike, Peter, Lurz, Philipp, and Pfister, Roman

Published
2022
Full Text
View/download PDF

2. Short term outcome after left atrial appendage occlusion with the AMPLATZER Amulet and WATCHMAN device: results from the ORIGINAL registry (saxOnian RegIstry analyzinG and followINg left atrial Appendage cLosure)

Author

Kretzler, Lucie, Mues, Christoph, Wunderlich, Carsten, Langbein, Anke, Spitzer, S. G., Gerk, Ulrich, Schellong, Sebastian, Ketteler, Thomas, Neuser, Hans, Schwefer, Marcus, Strasser, Ruth, Ibrahim, Karim, Schoen, Steffen, and Christoph, Marian

Published
2022
Full Text
View/download PDF

3. German Multicenter Experience With a New Leaflet-Based Transcatheter Mitral Valve Repair System for Mitral Regurgitation

Author

Mauri, Victor, Besler, Christian, Riebisch, Matthias, Al-Hammadi, Osamah, Ruf, Tobias, Gerçek, Muhammed, Horn, Patrick, Grothusen, Christina, Mehr, Michael, Becher, Marc Ulrich, Mues, Christoph, Boeder, Niklas, Kreidel, Felix, Friedrichs, Kai, Westenfeld, Ralf, Braun, Daniel, Öztürk, Can, Baldus, Stephan, Rassaf, Tienush, Thiele, Holger, Nickenig, Georg, Hausleiter, Jörg, Möllmann, Helge, Kelm, Malte, Rudolph, Volker, von Bardeleben, Ralph-Stephan, Nef, Holger M., Luedike, Peter, Lurz, Philipp, and Pfister, Roman

Published
2020
Full Text
View/download PDF

4. Early Outcomes of Two Large Mitral Valve Transcatheter Edge-to-Edge Repair Devices—A Propensity Score Matched Multicenter Comparison.

Author

von Stein, Philipp, Wienemann, Hendrik, von Stein, Jennifer, Sugiura, Atsushi, Tanaka, Tetsu, Kavsur, Refik, Öztürk, Can, Weber, Marcel, Haurand, Jean Marc, Horn, Patrick, Kister, Tobias, Mahabadi, Amir Abbas, Boeder, Niklas, Ruf, Tobias, Gerçek, Muhammed, Mues, Christoph, Grothusen, Christina, Novotny, Julia, Weckbach, Ludwig, and Guthoff, Henning

Subjects
MITRAL valve, MITRAL valve insufficiency, PROPENSITY score matching, CRIME & the press, ECHOCARDIOGRAPHY
Abstract

Background/Objectives: Previous trials reported comparable results with PASCAL and earlier MitraClip generations. Limited comparative data exist for more contemporary MitraClip generations, particularly the large MitraClip XT(R/W). We aimed to evaluate acute and 30-day outcomes in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) with one of the large devices, either PASCAL P10 or MitraClip XT(R/W) (3rd/4th generation). Methods: A total of 309 PASCAL-treated patients were matched by propensity score to 253 MitraClip-treated patients, resulting in 200 adequately balanced pairs. Procedural, clinical, and echocardiographic outcomes were collected for up to 30 days, including subgroup analysis for mitral regurgitation (MR) etiologies. Results: PASCAL and MitraClip patients were comparable regarding age (80 vs. 79 years), sex (female: 45.5% vs. 50.5%), and MR etiology (degenerative MR: n = 94, functional MR [FMR]: n = 96, mixed MR: n = 10 in each group). Technical success rates were comparable (96.5% vs. 96.0%; p > 0.999). At discharge, the mean gradient was higher (3.3 mmHg vs. 3.0 mmHg; p = 0.038), and the residual mitral valve orifice area was smaller in MitraClip patients (3.0 cm2 vs. 2.3 cm2; p < 0.001). At discharge, the reduction to MR ≤ 2+ was comparable (92.4% vs. 87.8%; p = 0.132). However, reduction to MR ≤ 1+ was more frequently observed in PASCAL patients (67.7% vs. 56.6%; p = 0.029), driven by the FMR subgroup (74.0% vs. 60.0%; p = 0.046). No difference was observed in 30-day mortality (p = 0.204) or reduction in NYHA-FC to ≤II (p > 0.999). Conclusions: Both M-TEER devices exhibited high and comparable rates of technical success and MR reduction to ≤2+. PASCAL may be advantageous in achieving MR reduction to ≤1+ in patients with FMR. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. TCT CONNECT-333 German Multicenter Experience With a New Leaflet-Based Transcatheter Mitral Valve Repair System for Mitral Regurgitation

Author

Mauri, Victor, primary, Riebisch, Matthias, additional, Ruf, Tobias, additional, Gerçek, Muhammed, additional, Horn, Patrick, additional, Grothusen, Christina, additional, Mehr, Michael, additional, Mues, Christoph, additional, Boeder, Niklas, additional, Kreidel, Felix, additional, Friedrichs, Kai, additional, Westenfeld, Ralf, additional, Braun, Daniel, additional, Öztürk, Can, additional, Baldus, Stephan, additional, Rassaf, Tienush, additional, Thiele, Holger, additional, Nickenig, Georg, additional, Hausleiter, Jörg, additional, Möllmann, Helge, additional, Rudolph, Volker, additional, Stephan von Bardeleben, Ralph, additional, Nef, Holger, additional, Luedike, Peter, additional, Lurz, Philipp, additional, and Pfister, Roman, additional

Published
2020
Full Text
View/download PDF

8. Untersuchungen zum Einfluss des oralen Antidiabetikums Metformin auf die hepatische Glukoseproduktion im Zellmodell

Author

Mues, Christoph Alexander and Medizin

Subjects
Proteinkinasen, Diabetes mellitus / Typ 2, Glukoneogenese, Insulin, Biguanide, ddc:610
Abstract

Wichtigster Befund dieser Arbeit ist, dass Metformin die Promotoraktivität der Glukose-6-Phosphatase (G6Pase) konzentrationsabhängig hemmt. Insulin hemmt die G6Pase Promotoraktivität stärker als Metformin. Unter Bedingungen gesteigerter G6Pase Promotoraktivität verstärkt sich die Metforminwirkung und ist mit der Wirkung von Insulin vergleichbar. Dabei werden die Effekte von Metformin und Insulin auf die G6Pase Promotoraktivität teilweise durch AMP- activated protein kinase (AMPK) vermittelt. Unter Bedingungen erhöhter G6Pase Promotoraktivität ist die Metforminwirkung auf den G6Pase Promotor stärker AMPK abhängig als die Insulinwirkung. In jedem Fall ist eine Steigerung der AMPK-Aktivität entscheidend für die Hemmung des G6Pase Promotors durch Metformin. Metformin nutzt zur Vermittlung seiner Effekte bis zur Ebene der Proteinkinase B (PKB) keine Schritte der Insulinsignaltransduktion. Der Metformineffekt muss unterhalb der PKB Anschluss an die Insulinsignaltransduktion haben.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results